TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer
We show for the first time in advanced TC that the presence of TP53 alterations is a predictor of poor response to LEN treatment and is associated with worse PFS and OS rates. The evaluation of TP53 mutations/p53 expression might be included in the patient/tumor characterization to be performed before starting an MKI treatment.
Authors
- Delfina Tosi (ORCID: https://orcid.org/0000-0002-6130-2665)
- Stefano Ferrero (ORCID: https://orcid.org/0000-0002-3715-0737)
- Gianlorenzo Dionigi (ORCID: https://orcid.org/0000-0003-0864-6087)
- Valentina Cirello (ORCID: https://orcid.org/0000-0002-8795-5226)
- Carla Maria Colombo (ORCID: https://orcid.org/0000-0003-0716-481X)
- Giacomo Gazzano (ORCID: https://orcid.org/0000-0002-7416-4644)
- Umberto Gianelli (ORCID: https://orcid.org/0000-0003-3304-8417)
- Laura Fugazzola (ORCID: https://orcid.org/0000-0001-5372-0982)
- Alessandro Manzo (ORCID: https://orcid.org/0000-0002-9461-3128)
- María Orietta Borghi (ORCID: https://orcid.org/0000-0001-8967-9678)
- Luca Persani (ORCID: https://orcid.org/0000-0003-2068-9581)
Institutions
- AOL (United States) (US)
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- IRCCS Istituto Auxologico Italiano (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1210/clinem/dgaf056
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero della Salute